Article

Regeneron, Geisinger collaborate for research

Regeneron Pharmaceuticals and Geisinger Health System have announced a major research collaboration focused on studying the genetic determinants of human disease.

 

Tarrytown, NY-Regeneron Pharmaceuticals and Geisinger Health System have announced a major research collaboration focused on studying the genetic determinants of human disease.

“We are pleased to be embarking on this next generation human genetic sequencing project with Geisinger,” said Leonard S. Schleifer, MD, PhD, president and chief executive officer of Regeneron.

The new research collaboration will include one of the largest US-populations of participants for the analysis and sequencing of genetic material and comparison to long-term health outcomes.

During the 5-year collaboration term, Geisinger plans to collect samples from more than 100,000 consented patient volunteers, while Regeneron-through its wholly-owned subsidiary, Regeneron Genetics Center LLC-will perform sequencing and genotyping to generate de-identified genomic data.

The size and scope of the study are meant to allow great precision in identifying and validating the associations between gene and human disease.

“For Geisinger, this relationship is about the potential to improve individualized patient care,” said David H. Ledbetter, PhD, executive vice president and chief scientific officer of Geisinger. “We expect that many of our patients will directly benefit from their participation in this research because of Geisinger’s ability to validate and return clinically actionable results to them, and all of our patients will benefit from the knowledge we gain I how to help set the standard for genomically informed care.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.